1. |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957.
|
2. |
Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153):561-566.
|
3. |
Casaluce F, Sgambato A, Maione P, et al. ALK inhibitors:a new targeted therapy in the treatment of advanced NSCLC[J]. Target Oncol, 2013, 8(1):55-67.
|
4. |
Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK[J]. J Clin Oncol, 2009, 27(26):4247-4253.
|
5. |
刘标, 时姗姗, 王璇, 等. 2011年肺腺癌新分类在评估组织学类型与分子学改变相关性中的意义[J]. 中华病理学杂志, 2012, 41(8):505-510.
|
6. |
Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer[J]. N Engl J Med, 2014, 371(23):2167-2177.
|
7. |
Shaw AT. Phase Ⅲ trial shows crizotinib superior to single-agent chemotherapy for ALK-positive advanced NSCLC[EB/OL]. (2012-09-30)[2015-03-26]. http:www.esmo.org/conferences/Past-Conferences/ESMO-2012-Congress/Congress-News/Phass-Ⅲ-trial-shows-crizotinib-superior-to-single-agent-chemotherly-for-Alk-adoanced-NSCLS.
|
8. |
Crinò L, Kim G, Riely GJ, et al. Initial phase Ⅱ results with crizotinibin advanced ALK-positive non small cell lung cancer(NSCLC):PROFILE 1005[J]. J Clin Oncol, 2011, 29(Suppl):abstr 7514.
|
9. |
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer[J]. N Engl J Med, 2013, 368(25):2385-2394.
|
10. |
Chung WS, Park MS, Shin SJ, et al. Response evaluation in patients with colorectal liver metastases:RECIST version. 1 versus modfiied CT criteria[J]. AJR Am J Roentgenol, 2012, 199(4):809-815.
|
11. |
CALGB. CTCAE v 4.0:common terminology criteria for adverse events[EB/OL].[2016-01-11]. http://www.calgb.org/Public/meetings/presentations/2009/summer_group/cra_cont_ed/06a_CTCAE-Setser_062009.pdf.
|
12. |
Takahashi T, Sonobe M, Kobayashi MA, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene[J]. Ann Surg Oncol, 2010, 17(3):889-897.
|
13. |
Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population[J]. Clin Cancer Res, 2009, 15(16):5216-5223.
|
14. |
Yang JJ, Zhang XC, Su J, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements:diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation[J]. Clin Cancer Res, 2014, 20(5):1383-1392.
|
15. |
Zhao N, Zheng SY, Yang JJ, et al. Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors:a case report and literature review[J]. Clin Lung Cancer, 2015, 16(2):E5-E9.
|
16. |
Cao Y, Xiao G, Qiu X, et al. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients[J]. PLoS One, 2014, 9(12):e114008.
|